Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neuraltus Pharmaceuticals has received three grants totaling $733,437 under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP), to advance Neuraltus' product pipeline, including NP001, NP002 and NP003.
Subscribe to our email newsletter
The grants are being provided under section 48D of the Internal Revenue Code, enacted as part of the Patient Protection and Affordable Care Act of 2010.
NP001 is a new small molecule that regulates macrophage activation, with potential application to a number of neurodegenerative diseases, including ALS, Alzheimer’s disease, Parkinson’s disease and multiple sclerosis.
Neuraltus currently is evaluating NP001 for the treatment of Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s disease) in an ongoing Phase 1 study.
NP002, a nicotinic receptor agonist, currently is in a Phase 1/2 study for L-dopa-induced dyskinesias (muscle movement disorders).
NP003, an orally bioavailable, small molecule, is designed to treat lysosomal storage disorders such as Fabry’s disease and Gaucher’s disease, as well as Parkinson’s disease.
Neuraltus president and CEO Andrew Gengos said that they were pleased to receive the grant. With the help of the QTDP grant, Neuraltus will be able to further develop NP001, NP002 and NP003.